We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

66 hedge funds and large institutions have $245M invested in Xenon Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 3

69% more capital invested

Capital invested by funds: $145M → $245M (+$100M)

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

22% more funds holding

Funds holding: 54 → 66 (+12)

9.87% more ownership

Funds ownership: 62.44% → 72.3% (+9.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
66
Holders Change
+12
Holders Change %
+22.22%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
19
Reduced
14
Closed
3
Calls
$253K
Puts
–
Net Calls
+$253K
Net Calls Change
+$252K

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.57M
2
NMC
NEA Management Company
Maryland
+$4.1M
3
ACM
Aquilo Capital Management
California
+$2.26M
4
ACP
Acuta Capital Partners
California
+$2.26M
5
BI
BVF Inc
California
+$2.18M

Top Sellers

1
BlackRock
BlackRock
New York
-$2.31M
2
DCM
DAFNA Capital Management
California
-$861K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$728K
4
Squarepoint
Squarepoint
New York
-$579K
5
AA
ALPS Advisors
Colorado
-$463K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$1.01M +$808K +76,817 New
SSA
27
Schonfeld Strategic Advisors
New York
$910K +$730K +69,400 New
SC
28
Scotia Capital
Ontario, Canada
$820K -$40K -3,799 -6%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$768K -$38.9K -3,700 -6%
JP Morgan Chase
30
JP Morgan Chase
New York
$768K +$394K +37,461 +177%
BFM
31
Boothbay Fund Management
New York
$669K – – –
MCM
32
Moore Capital Management
New York
$656K – – –
Marshall Wace
33
Marshall Wace
United Kingdom
$637K +$511K +48,606 New
Millennium Management
34
Millennium Management
New York
$626K +$502K +47,714 New
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$615K +$168K +15,979 +52%
Royal Bank of Canada
36
Royal Bank of Canada
Ontario, Canada
$611K -$376K -35,790 -43%
PNC Financial Services Group
37
PNC Financial Services Group
Pennsylvania
$599K – – –
Northern Trust
38
Northern Trust
Illinois
$579K +$68.4K +6,507 +17%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$434K +$65.2K +6,200 +23%
Squarepoint
40
Squarepoint
New York
$421K -$579K -55,023 -63%
CSS
41
Cubist Systematic Strategies
Connecticut
$335K +$251K +23,871 +1,452%
NSEDCP
42
NJ State Employees Deferred Compensation Plan
New Jersey
$328K – – –
Russell Investments Group
43
Russell Investments Group
United Kingdom
$320K -$132K -12,544 -34%
State Street
44
State Street
Massachusetts
$267K -$3.2K -304 -1%
Geode Capital Management
45
Geode Capital Management
Massachusetts
$252K – – –
EWM
46
Elmwood Wealth Management
California
$246K – – –
HF
47
HRT Financial
New York
$238K +$192K +18,220 New
MWNA
48
Marshall Wace North America
New York
$196K +$157K +14,939 New
FPC
49
Falcon Point Capital
California
$170K – – –
Goldman Sachs
50
Goldman Sachs
New York
$170K +$25.3K +2,408 +23%
1
2
3

XENE Hedge Fund Activity: Q4 2019 in Review

66 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2019, worth a combined $245M — up 69% from $145M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new XENE positions and 3 closed out — a net gain of 12 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $6.57M. The largest seller was BlackRock, exiting entirely with an estimated $2.31M sold.

  • 66 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2019, up from 54 in Q3 2019.
  • Funds reported $245M of Xenon Pharmaceuticals stock for Q4 2019, up 69% quarter-over-quarter.
  • 15 funds opened new Xenon Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of +12 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2019 was Adage Capital Partners, an estimated $6.57M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2019.